The progress in viral vector manufacturing and gene editing means orthopedic specialists may soon be able to offer treatments that genuinely restore cartilage, not just mask symptoms. Ongoing developments focus on increasing the specificity of gene delivery, enhancing the durability of therapeutic effects, and scaling up production methods to allow widespread clinical adoption.
